Erythème chronique migrant
Peer reviewed by Dr Doug McKechnie, MRCGPLast updated by Dr Colin Tidy, MRCGPLast updated 12 Jun 2023
Répond aux besoins du patient lignes directrices éditoriales
- TéléchargerTélécharger
- Partager
Professionnels de la santé
Les articles de référence professionnelle sont destinés aux professionnels de la santé. Ils sont rédigés par des médecins britanniques et s'appuient sur les résultats de la recherche ainsi que sur les lignes directrices britanniques et européennes. Vous trouverez peut-être l'un de nos articles sur la santé plus utile.
Dans cet article :
Poursuivre la lecture ci-dessous
What is erythema chronicum migrans?
Erythema chronicum migrans is a characteristic clinical feature of Lyme disease (Lyme borreliosis). It is a distinctive rash, which occurs in the majority of people infected with Borrelia burgdorferi. This infection is transmitted to humans by the bite of a tick from the genus Ixodes.
How common is erythema chronicum migrans? (Epidemiology)1
Lyme disease is not common in the UK, with an estimated 2,000 to 3,000 new cases each year in England and Wales.
In the UK, areas where infection is acquired include Exmoor, the New Forest, the South Downs, parts of Wiltshire and Berkshire, Surrey, West Sussex, Thetford Forest, the Lake District, the North Yorkshire moors and the Scottish Highlands.
Infection may also be acquired abroad and mostly by holidaymakers. The majority are acquired in the USA, France, Germany, Scandinavia and other northern, eastern and central European countries. The infection can also be found in temperate forested areas of Asia, including Russia, China and Japan.
In Europe erythema chronicum migrans occurs as a presenting feature in up to 90% of those infected.2 Presentation does appear to depend upon the Borrelia species involved; therefore, in other parts of the world the rash may be a less common presenting sign.
Poursuivre la lecture ci-dessous
Symptoms of erythema chronicum migrans (presentation)3
The characteristic manifestation of early Lyme disease (stage 1) is erythema chronicum migrans: a circular rash at the site of the infectious tick attachment, which radiates from the bite. It can appear within 3-36 days, but typically in 7-10.
It starts as a red macule or papule at the site of the tick bite after a (typically 7- to 10-day) delay.
The rash is round or oval, and pink, red or purple. There is often central sparing giving a target-like appearance, and the diameter is usually larger than 5 cm. The nature of the rash and the likelihood of its presence are partly dependent on the species involved and therefore differ between continents.
Erythème migrant de la maladie de Lyme
Untreated, this can last for some weeks, but eventually resolves.
Common areas include the popliteal fossa, groin, the axilla, the thorax and the trunk. The hairline and scalp are especially common in children.
It may be associated with other symptoms of infection, including fatigue, myalgia, arthralgia, headache, fever, stiff neck, and regional lymphadenopathy.
It may also be associated with later developments such as carditis, neurological disease, arthritis, and acrodermatitis chronica atrophicans (a swollen, bluish-red skin lesion on a distal extremity).
The National Institute for Health and Care Excellence (NICE) recommends diagnosing Lyme disease in people with erythema migrans that:4
Increases in size and may sometimes have a central clearing.
Is not usually itchy, hot or painful.
Usually becomes visible from 1 to 4 weeks (but can appear from 3 days to 3 months) after a tick bite and lasts for several weeks.
Is usually at the site of a tick bite.
In the absence of erythema migrans, the diagnosis of Lyme disease can be very difficult with non-specific clinical signs and symptoms that may or may not be supported by laboratory evidence.5
Diagnostic différentiel6
Local tick bite reactions.
Poursuivre la lecture ci-dessous
Enquêtes1 3
For anyone with erythema migrans who have no evidence of focal symptoms of Lyme disease (eg neurological, cardiac, or joint involvement), investigations are not required and start treatment with oral antibiotics (see below).
Management of erythema chronicum migrans4 7
Although the rash will resolve spontaneously over weeks or months, antibiotics help prevent progression to disseminated Lyme disease.
For the treatment of Lyme disease without focal symptoms (eg, neurological, carditis) but with erythema migrans and/or non-focal symptoms, NICE recommends:
First choice: oral doxycycline: 100 mg twice per day or 200 mg once per day for 21 days.
First alternative: oral amoxicillin: 1 g 3 times per day for 21 days.
Second alternative: oral azithromycin: 500 mg daily for 17 days (azithromycin should not be used to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval).
Prevention of erythema chronicum migrans
Avoid exposure to tick bites.
Remove ticks as soon as possible. Ticks take some time to transmit infection, so this may be prevented if removed quickly.
Antibiotic prophylaxis can be offered in endemic areas under certain circumstances if the tick bite can be positively identified.
Autres lectures et références
- Mygland A, Ljostad U, Fingerle V, et al; EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010 Jan;17(1):8-16, e1-4. doi: 10.1111/j.1468-1331.2009.02862.x. Epub 2009 Nov 23.
- Erythème chronique migrantDermIS (Système d'information dermatologique)
- Prevention and control of tick-borne disease in Europe - Information to healthcare professionalsCentre européen de prévention et de contrôle des maladies
- Coburn J, Garcia B, Hu LT, et alPathogenèse de la maladie de Lyme. Curr Issues Mol Biol. 2021;42:473-518. doi : 10.21775/cimb.042.473. Epub 2020 Dec 23.
- Lyme disease (and erythema migrans); Primary Care Dermatology Society (PCDS). Last updated May 2022.
- Maladie de Lyme; DermNet.
- Maladie de Lyme : orientations, données et analysesPublic Health England - maintenant UK Health Security Agency (dernière mise à jour 2022)
- The epidemiology, prevention, investigation and treatment of Lyme borreliosis in United Kingdom patients: a position statement by the British Infection Association; J Infect. 2011 May;62(5):329-38. doi: 10.1016/j.jinf.2011.03.006. Epub 2011 Mar 21.
- Maladie de LymeNICE CKS, novembre 2022 (accès réservé au Royaume-Uni)
- Maladie de LymeNICE Guidance (avril 2018 - dernière mise à jour en octobre 2018)
- Bobe JR, Jutras BL, Horn EJ, et alLes progrès récents dans la maladie de Lyme et les défis qui restent à relever. Front Med (Lausanne). 2021 Aug 18;8:666554. doi : 10.3389/fmed.2021.666554. eCollection 2021.
- Shapiro EDPratique clinique. Maladie de Lyme. N Engl J Med. 2014 May 1;370(18):1724-31. doi : 10.1056/NEJMcp1314325.
- British National Formulary (BNF)NICE Evidence Services (accès au Royaume-Uni uniquement)
Poursuivre la lecture ci-dessous
Historique de l'article
Les informations contenues dans cette page sont rédigées et évaluées par des cliniciens qualifiés.
Prochaine révision prévue : 12 mai 2028
12 Jun 2023 | Dernière version

Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets liés à la santé.

Vous ne vous sentez pas bien ?
Évaluez gratuitement vos symptômes en ligne